Heska (NASDAQ:HSKA) Price Target Raised to $220.00 at Piper Sandler
Heska (NASDAQ:HSKA) had its price target lifted by research analysts at Piper Sandler from $157.00 to $220.00 in a report issued on Tuesday, The Fly reports. The firm currently has an “overweight” rating on the medical research company’s stock. Piper Sandler’s price objective would suggest a potential upside of 11.94% from the company’s previous close.
Other research analysts also recently issued research reports about the stock. JPMorgan Chase & Co. began coverage on shares of Heska in a research report on Friday, January 29th. They issued an “overweight” rating and a $195.00 price objective for the company. Raymond James increased their price objective on shares of Heska from $140.00 to $145.00 and gave the company an “outperform” rating in a report on Thursday, November 19th. TheStreet upgraded Heska from a “d+” rating to a “c-” rating in a research note on Tuesday, October 27th. Alliance Global Partners boosted their price objective on Heska from $116.50 to $163.50 and gave the company a “buy” rating in a report on Wednesday, November 4th. Finally, Zacks Investment Research downgraded Heska from a “hold” rating to a “sell” rating in a report on Wednesday, February 17th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $143.92.
Shares of HSKA traded up $7.98 during trading hours on Tuesday, reaching $196.53. 91,966 shares of the company traded hands, compared to its average volume of 65,270. The stock has a market capitalization of $1.86 billion, a P/E ratio of -88.53 and a beta of 1.65. The company has a quick ratio of 3.79, a current ratio of 4.96 and a debt-to-equity ratio of 0.18. Heska has a 12-month low of $50.00 and a 12-month high of $206.85. The business has a fifty day moving average price of $174.18 and a 200-day moving average price of $130.76.
Institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. lifted its position in shares of Heska by 2.8% during the 3rd quarter. BlackRock Inc. now owns 1,298,015 shares of the medical research company’s stock worth $128,232,000 after purchasing an additional 35,111 shares during the last quarter. Morgan Stanley grew its position in shares of Heska by 28.7% in the 3rd quarter. Morgan Stanley now owns 32,026 shares of the medical research company’s stock valued at $3,164,000 after purchasing an additional 7,145 shares during the period. Legal Advantage Investments Inc. acquired a new position in Heska during the 4th quarter worth approximately $4,129,000. Charles Schwab Investment Management Inc. raised its stake in Heska by 2.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 54,052 shares of the medical research company’s stock valued at $5,340,000 after acquiring an additional 1,150 shares during the period. Finally, BNP Paribas Arbitrage SA increased its position in Heska by 251.2% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 1,907 shares of the medical research company’s stock worth $188,000 after buying an additional 1,364 shares during the period. Hedge funds and other institutional investors own 96.11% of the company’s stock.
Heska Company Profile
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.